US Federal 2025-2026 Regular Session

US Federal Senate Bill SB3797

Introduced
2/5/26  

Caption

Prohibiting Tianeptine and Other Dangerous Products Act of 2026

Impact

The impact of SB3797 on state laws primarily involves an increase in federal oversight of dietary supplements, which could lead to stricter enforcement against products that have not been adequately reviewed for safety. By prohibiting the delivery of certain non-compliant supplements into interstate commerce, the bill aims to prevent potentially dangerous substances from being marketed. In addition, it enhances seizure authorities concerning these products, thus providing federal authorities with greater power to act against violations within the dietary supplement market.

Summary

SB3797, titled the 'Prohibiting Tianeptine and Other Dangerous Products Act of 2026', aims to amend the Federal Food, Drug, and Cosmetic Act by establishing new prohibited acts related to dietary supplements. This legislative change specifically targets the introduction of dietary supplements that do not comply with defined criteria under the current law, particularly focusing on products like Tianeptine, which have raised safety concerns. The bill intends to enhance consumer protection and ensure that marketed dietary supplements meet established safety standards.

Contention

Notable points of contention surrounding SB3797 may revolve around the balance between ensuring consumer safety and the potential for overregulation. Proponents of the bill argue that it is necessary to prevent harmful substances from entering the market, citing health risks associated with unregulated dietary supplements. Conversely, critics may express concerns about the implications for manufacturers and consumers, including the possibility of limiting the availability of beneficial supplements that fall under the new prohibited acts. The discourse may also include discussions on the effectiveness of current regulations versus the need for additional measures.

Companion Bills

US HB7407

Same As Prohibiting Tianeptine and Other Dangerous Products Act of 2026

Previously Filed As

US HB7407

Prohibiting Tianeptine and Other Dangerous Products Act of 2026

US AB634

Tianeptine.

US S322

Establishes tianeptine as Schedule II controlled dangerous substance.

US S670

Requires producers of plastic packaging and certain other plastic products to reduce quantity of plastic sold; restricts additional substances under "Toxic Packaging Reduction Act."

US HB1720

TIANEPTINE PROHIBITION ACT

US A3725

Requires producers of plastic packaging and certain other plastic products to reduce quantity of plastic sold; restricts additional substances under "Toxic Packaging Reduction Act."

US SB3677

Dietary Supplement Listing Act of 2026

US HB1282

Tobacco Products, Other Tobacco Products, and Electronic Smoking Devices - Advertising to Minors - Prohibition

US HB8385

Food Labeling Modernization Act of 2026

US SB292

Prohibiting the transfer of hemp-derived cannabinoid products to any person under the age of 21, establishing packaging and labeling requirements for such products and amending the definition of industrial hemp and hemp products.

Similar Bills

No similar bills found.